Welcome to EQUITY DEVELOPMENT

The UK's longest established regulated provider of sponsored equity research.

We launched EQUITY DEVELOPMENT in 1997 becoming the first ever  regulated provider of Sponsored Equity Research in the UK.

Our research teams are made up of expert analysts with deep understanding & experience in their sectors.  Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).

We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.

 

FREE REGISTRATION

Sign up today and access the very latest company research

LOG IN

For access to all company research please

Sinclair Pharma

Sinclair Pharma plc acquires late stage patented products in the fields of dermatology, oral health and oncology support. It develops and registers these products before licensing them to marketing partners or selling them through their own sales force in key European markets.

Sinclair Pharma; Full review of results/license deal/acquisition

  • GCSD purchased in France
  • Decapinol licensed in USA
  • Profitabilty forecast for 2007

Publication Date:
July 4 2006

Sinclair Pharma; successfully executing strategy

  • Over 30 licensing agreements in FY 2005
  • Italian acquisition contributing over £1m
  • Healthy cash position, bolstered by £7m issue
  • Reassuring Pre Close period update
  • Fair value/ share: 195-202p vs current 135p

Publication Date:
January 19 2006

Sinclair Pharma; R&D update

Sinclair Pharma’s financial year has successfully drawn to an end with an extensive number of regulatory approvals in both the US and EU, 31 commercial agreements signed worldwide over the period, and a company acquisition in Italy.

Publication Date:
July 4 2005

Sinclair Pharma; Acquisition and product progress

  • Decapinol approved by FDA
  • Acquisition of Euroderm RDC
  • Good news flow
  • Fair value still seen as 165p a share

Publication Date:
May 25 2005

Sinclair Pharma; License for change

  • US licence agreement for Atopiclair™ with Chester Valley Pharmaceuticals
  • Acquisition of Euroderm-RDC SpA
  • First European distribution agreement for Decapinol®
  • Significant enhancement of the company’s prospects
  • Fair Value of 165p

Publication Date:
January 14 2005

next